/SPRB
SPRB Stock - Spruce Biosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$78.74+2.57%
+$1.97 (+2.57%) • Dec 19
45
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+184.9%upside
Target: $224.33
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SPRB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$77.95 – $79.53
TARGET (TP)$224.33
STOP LOSS$72.44
RISK/REWARD1:23.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.51
52W High$2542.50
52W Low$7.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.91M | $10.09M | N/A | N/A | N/A |
| Gross Profit | $4.91M | $10.09M | N/A | N/A | N/A |
| Gross Margin | 100.0% | 100.0% | N/A | N/A | N/A |
| Operating Income | $-56,151,000 | $-51,993,000 | $-47,283,000 | $-42,066,000 | $-29,416,000 |
| Net Income | $-53,036,000 | $-47,919,000 | $-46,180,000 | $-42,292,000 | $-29,539,000 |
| Net Margin | -1079.9% | -475.0% | N/A | N/A | N/A |
| EPS | $-96.75 | $-93.00 | $-72.00 | $-68.25 | $-48.75 |
Company Overview
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
50%
Hold / Neutral
3
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
3 Bullish3 Neutral/Bearish
Price Targets
$86
Average Target
↑ 8.7% Upside
Now
$2
Low
$86
Average
$254
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 3rd 2025 | Leerink Partners | Upgrade | Outperform | $160 |
| October 28th 2025 | Citizens JMP | Upgrade | Mkt Outperform | $254 |
| December 11th 2024 | JMP Securities | Downgrade | Market Perform | - |
| December 11th 2024 | Oppenheimer | Downgrade | Perform | - |
| March 14th 2024 | Guggenheim | Downgrade | Neutral | - |
| March 14th 2024 | Leerink Partners | Downgrade | Market Perform | $2← $9 |
| March 14th 2024 | RBC Capital Mkts | Downgrade | Sector Perform | $2← $9 |
| March 14th 2024 | Ladenburg Thalmann | Downgrade | Neutral | - |
| March 14th 2024 | H.C. Wainwright | Downgrade | Neutral | - |
| February 21st 2024 | Guggenheim | Initiation | Buy | $10 |
Earnings History & Surprises
SPRBBeat Rate
79%
Last 19 quarters
Avg Surprise
-1.1%
EPS vs Estimate
Beats / Misses
15/4
Last 12 quarters
Latest EPS
$-14.58
Q4 2025
EPS Surprise History
Q1 24
+43.9%
$-0.23vs$-0.41
Q2 24
+12.5%
$-0.28vs$-0.32
Q3 24
+33.3%
$-0.22vs$-0.33
Q4 24
+22.2%
$-0.21vs$-0.27
Q1 25
-137.9%
$-0.57vs$-0.24
Q2 25
-171.4%
$-0.57vs$-0.21
Q3 25
+80.6%
$-3.50vs$-18.05
Q4 25
+6.3%
$-14.58vs$-15.56
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 21, 2026 | $-6.52 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-15.56 | $-14.58 | +6.3% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-18.05 | $-3.50 | +80.6% | ✓ BEAT |
Q2 2025 | Apr 15, 2025 | $-0.21 | $-0.57 | -171.4% | ✗ MISS |
Q1 2025 | Mar 26, 2025 | $-0.24 | $-0.57 | -137.9% | ✗ MISS |
Q4 2024 | Nov 11, 2024 | $-0.27 | $-0.21 | +22.2% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.33 | $-0.22 | +33.3% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.32 | $-0.28 | +12.5% | ✓ BEAT |
Q1 2024 | Mar 13, 2024 | $-0.41 | $-0.23 | +43.9% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.34 | $-0.30 | +11.8% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.37 | $-0.32 | +13.5% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.42 | $-0.40 | +4.8% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $-0.55 | $-0.47 | +14.5% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.54 | $-0.48 | +11.1% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-0.54 | $-0.51 | +5.6% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-0.45 | $-0.50 | -11.1% | ✗ MISS |
Q1 2022 | Mar 14, 2022 | $-0.57 | $-0.39 | +31.6% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-0.57 | $-0.49 | +14.0% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-0.45 | $-0.50 | -11.1% | ✗ MISS |
Q2 2021 | May 12, 2021 | $-0.44 | $-0.42 | +4.5% | ✓ BEAT |
Frequently Asked Questions about SPRB
What is SPRB's current stock price?
Spruce Biosciences, Inc. (SPRB) is currently trading at $78.74 per share. The stock has moved +2.57% today.
What is the analyst price target for SPRB?
The average analyst price target for SPRB is $224.33, based on 1 analyst.
What sector is Spruce Biosciences, Inc. in?
Spruce Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SPRB's market cap?
Spruce Biosciences, Inc. has a market capitalization of $0.05 billion, making it a small-cap company.
Does SPRB pay dividends?
No, Spruce Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCOEP
Coeptis Therapeutics, Inc.
$14.66
Mkt Cap: $0.1B
CUE
Cue Biopharma, Inc.
$0.27
Mkt Cap: $0.0B
EQ
Equillium, Inc.
$1.15
Mkt Cap: $0.0B
HOWL
Werewolf Therapeutics, Inc.
$0.69
Mkt Cap: $0.0B
IOBT
IO Biotech, Inc.
$0.66
Mkt Cap: $0.0B
NRXP
NRx Pharmaceuticals, Inc.
$2.37
Mkt Cap: $0.0B
OSTX
OS Therapies Incorporated
$1.54
Mkt Cap: $0.1B
OTLK
Outlook Therapeutics, Inc.
$2.01
Mkt Cap: $0.1B
VTVT
vTv Therapeutics Inc.
$36.01
Mkt Cap: $0.1B
Explore stocks similar to SPRB for comparison